A Comparison of SCH 56592 and Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients
- Conditions
- Candidiasis, OralHIV Infections
- Registration Number
- NCT00002399
- Lead Sponsor
- Schering-Plough
- Brief Summary
The purpose of this study is to compare the safety and effectiveness of SCH 56592 with that of fluconazole in the treatment of OPC (a fungal infection of the throat) in HIV-positive patients.
- Detailed Description
This is a randomized, multicenter, double-blind study consisting of 5 arms (4 dose levels of SCH 56592 vs fluconazole) in the treatment of oropharyngeal candidiasis (OPC) in HIV-positive patients.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 500
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (52)
Tucson Veterans Administration Med Ctr
🇺🇸Tucson, Arizona, United States
Northeast Arkansas Clinic
🇺🇸Jonesboro, Arkansas, United States
Miami Veterans Administration Med Ctr
🇺🇸Miami, Florida, United States
Mercy Hosp
🇺🇸Miami, Florida, United States
Ponce de Leon Med Ctr
🇺🇸Atlanta, Georgia, United States
Med College of Georgia
🇺🇸Augusta, Georgia, United States
Rush Med College / Rush Presbyterian - St Luke's Med Cen
🇺🇸Chicago, Illinois, United States
Wishard Hosp
🇺🇸Indianapolis, Indiana, United States
Wayne State Univ / Harper Hosp
🇺🇸Detroit, Michigan, United States
St Michaels Med Ctr
🇺🇸Newark, New Jersey, United States
Scroll for more (42 remaining)Tucson Veterans Administration Med Ctr🇺🇸Tucson, Arizona, United States